Literature DB >> 15117953

Requirement for aspartate-cleaved bid in apoptosis signaling by DNA-damaging anti-cancer regimens.

Arlette B Werner1, Stephen W G Tait, Evert de Vries, Eric Eldering, Jannie Borst.   

Abstract

Lymphoid malignancies can escape from DNA-damaging anti-cancer drugs and gamma-radiation by blocking apoptosis-signaling pathways. How these regimens induce apoptosis is incompletely defined, especially in cells with nonfunctional p53. We report here that the BH3-only Bcl-2 family member Bid is required for mitochondrial permeabilization and apoptosis induction by etoposide and gamma-radiation in p53 mutant T leukemic cells. Bid is not transcriptionally up-regulated in response to these stimuli but is activated by cleavage on aspartate residues 60 and/or 75, which are the targets of caspase-8 and granzyme B. Bid activity is not inhibitable by c-Flip(L), CrmA, or dominant negative caspase-9 and therefore is independent of inducer caspase activation by death receptors or the mitochondria. Caspase-2, which has been implicated as inducer caspase in DNA damage pathways, appeared to be processed in response to etoposide and gamma-radiation but downstream of caspase-9. Knock down of caspase-2 by short interfering RNA further excluded its role in Bid activation by DNA damage. Caspase-2 was implicated in the death receptor pathway however, where it contributed to effector caspase processing downstream of inducer caspases. Granzyme B-specific serpins could not block DNA damage-induced apoptosis, excluding a role for granzyme B in the generation of active Bid. We conclude that Bid, cleaved by an undefined aspartate-specific protease, can be a key mediator of the apoptotic response to DNA-damaging anticancer regimens.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15117953     DOI: 10.1074/jbc.M400268200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  17 in total

1.  Restraint of apoptosis during mitosis through interdomain phosphorylation of caspase-2.

Authors:  Joshua L Andersen; Carrie E Johnson; Christopher D Freel; Amanda B Parrish; Jennifer L Day; Marisa R Buchakjian; Leta K Nutt; J Will Thompson; M Arthur Moseley; Sally Kornbluth
Journal:  EMBO J       Date:  2009-09-03       Impact factor: 11.598

2.  BID preferentially activates BAK while BIM preferentially activates BAX, affecting chemotherapy response.

Authors:  Kristopher A Sarosiek; Xiaoke Chi; John A Bachman; Joshua J Sims; Joan Montero; Luv Patel; Annabelle Flanagan; David W Andrews; Peter Sorger; Anthony Letai
Journal:  Mol Cell       Date:  2013-09-26       Impact factor: 17.970

3.  Cleavage of Bid by executioner caspases mediates feed forward amplification of mitochondrial outer membrane permeabilization during genotoxic stress-induced apoptosis in Jurkat cells.

Authors:  Shary N Shelton; Mary E Shawgo; John D Robertson
Journal:  J Biol Chem       Date:  2009-02-19       Impact factor: 5.157

4.  Loss of caspase-9 reveals its essential role for caspase-2 activation and mitochondrial membrane depolarization.

Authors:  Ajoy K Samraj; Dennis Sohn; Klaus Schulze-Osthoff; Ingo Schmitz
Journal:  Mol Biol Cell       Date:  2006-11-01       Impact factor: 4.138

5.  Mutations to bid cleavage sites protect hepatocytes from apoptosis after ischemia/reperfusion injury.

Authors:  Erica Riddle-Taylor; Kazuhito Nagasaki; Joseph Lopez; Carlos O Esquivel; Olivia M Martinez; Sheri M Krams
Journal:  Transplantation       Date:  2007-09-27       Impact factor: 4.939

6.  Differential responses of FLIPLong and FLIPShort-overexpressing human myeloid leukemia cells to TNF-alpha and TRAIL-initiated apoptotic signals.

Authors:  Sudeshna Seal; David M Hockenbery; Emily Y Spaulding; Hans-Peter Kiem; Nissa Abbassi; H Joachim Deeg
Journal:  Exp Hematol       Date:  2008-10-05       Impact factor: 3.084

7.  Execution of superoxide-induced cell death by the proapoptotic Bcl-2-related proteins Bid and Bak.

Authors:  Muniswamy Madesh; Wei-Xing Zong; Brian J Hawkins; Subbiah Ramasamy; Thilagavathi Venkatachalam; Partha Mukhopadhyay; Patrick J Doonan; Krishna M Irrinki; Mohanraj Rajesh; Pál Pacher; Craig B Thompson
Journal:  Mol Cell Biol       Date:  2009-03-30       Impact factor: 4.272

Review 8.  The enigma of caspase-2: the laymen's view.

Authors:  G Krumschnabel; B Sohm; F Bock; C Manzl; A Villunger
Journal:  Cell Death Differ       Date:  2008-11-21       Impact factor: 15.828

9.  Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B.

Authors:  R W Rooswinkel; B van de Kooij; M Verheij; J Borst
Journal:  Cell Death Dis       Date:  2012-08-09       Impact factor: 8.469

10.  Pharmacological inhibition of caspase-2 protects axotomised retinal ganglion cells from apoptosis in adult rats.

Authors:  Vasanthy Vigneswara; Martin Berry; Ann Logan; Zubair Ahmed
Journal:  PLoS One       Date:  2012-12-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.